PriceTargets.com logo

Ambu A/S - AMBBY Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$14.18 As of 12/20/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for AMBBY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ambu A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMBBY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMBBY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Ambu A/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $14.18.

This chart shows the closing price for AMBBY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Ambu A/S. This rating has held steady since August 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/5/2023HandelsbankenUpgradeMarket Perform ➝ Outperform
3/2/2023DNB MarketsUpgradeHold ➝ Buy
12/14/2022JPMorgan Chase & Co.Boost TargetUnderweight ➝ Underweight64.00 ➝ 65.00
5/9/2022DanskeDowngradeBuy ➝ Hold
12/2/2021JPMorgan Chase & Co.Reiterated RatingUnderweight
11/10/2021JPMorgan Chase & Co.Reiterated RatingUnderweight
11/1/2021JPMorgan Chase & Co.Reiterated RatingUnderweight
8/18/2021Nordea Equity ResearchDowngradeHold ➝ Sell
8/18/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
7/5/2021DanskeUpgradeHold ➝ Buy
5/25/2021Berenberg BankReiterated RatingBuy
5/14/2021Morgan StanleyReiterated RatingOverweight
5/13/2021JPMorgan Chase & Co.Reiterated RatingNeutral
4/16/2021Morgan StanleyInitiated CoverageOverweight
3/29/2021DNB MarketsUpgradeSell ➝ Buy
2/11/2021JPMorgan Chase & Co.Reiterated RatingNeutral
1/28/2021DNB MarketsDowngradeHold ➝ Sell
1/20/2021DNB MarketsDowngradeBuy ➝ Hold
11/12/2020JPMorgan Chase & Co.Reiterated RatingNeutral
10/15/2020JPMorgan Chase & Co.Reiterated RatingNeutral
8/28/2020JPMorgan Chase & Co.Reiterated RatingNeutral
5/6/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
5/6/2020DanskeUpgradeSell ➝ Hold
4/28/2020Berenberg BankInitiated CoverageBuy
4/28/2020DanskeDowngradeBuy ➝ Sell
4/20/2020JPMorgan Chase & Co.Reiterated RatingOverweight
(Data available from 12/23/2019 forward)

News Sentiment Rating

-0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Ambu A/S logo
Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, CPR breathing barriers, video laryngoscopes, and training manikins. The company was founded in 1937 and is headquartered in Ballerup, Denmark.
Read More

Today's Range

Now: $14.18
Low: $14.18
High: $14.18

50 Day Range

MA: $16.72
Low: $14.18
High: $18.78

52 Week Range

Now: $14.18
Low: $14.18
High: $22.65

Volume

27 shs

Average Volume

685 shs

Market Capitalization

$3.33 billion

P/E Ratio

118.17

Dividend Yield

0.20%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Ambu A/S?

The following equities research analysts have issued stock ratings on Ambu A/S in the last twelve months:
View the latest analyst ratings for AMBBY.

What is the current price target for Ambu A/S?

0 Wall Street analysts have set twelve-month price targets for Ambu A/S in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Ambu A/S in the next year.
View the latest price targets for AMBBY.

What is the current consensus analyst rating for Ambu A/S?

Ambu A/S currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AMBBY.

What other companies compete with Ambu A/S?

Other companies that are similar to Ambu A/S include Cochlear, HORIBA, Morgan Stanley Direct Lending, Blue Owl Capital Co. III and Ryman Healthcare. Learn More about companies similar to Ambu A/S.

How do I contact Ambu A/S's investor relations team?

Ambu A/S's physical mailing address is Baltorpbakken 13, Ballerup 2750, Denmark. The company's listed phone number is (457) 225-2000 and its investor relations email address is [email protected]. The official website for Ambu A/S is www.ambu.com. Learn More about contacing Ambu A/S investor relations.